Companies Dominating the Aspergillosis Treatment Market
- Bayer AG
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- WOT Analysis
- Mayne Pharma Group Limited
- PULMATRiX Inc.
- Endo International plc
- Johnson & Johnson Services Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Abbott
- Takeda Pharmaceutical Company Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
2025 Aspergillosis Treatment Market is evaluated at USD 4.08 billion.
The global aspergillosis treatment market size was estimated at over USD 3.94 billion in 2024 and is anticipated to grow at a CAGR of 4.5%, with projections indicating it will exceed USD 6.98 billion by 2037.
North America is forecasted to register USD 2.93 billion by 2037, impelled by a high prevalence of lung diseases and immunocompromised conditions.
The major players in the market are Bayer AG, Mayne Pharma Group Limited, PULMATRiX Inc., Endo International Plc, Johnson & Johnson Services Inc., GlaxoSmithKline Plc, Pfizer Inc., Abbott, Takeda Pharmaceutical Company Limited, Novartis AG, Shionogi & Co., Ltd., Asahi Kasei Pharma Corporation, F2G Ltd., Regeneron Pharmaceutical Inc.
